Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Life Sci ; 76(3): 319-29, 2004 Dec 03.
Article in English | MEDLINE | ID: mdl-15531383

ABSTRACT

The use of local anesthetics, such as lidocaine, has been proposed in the treatment of distal ulcerative colitis. Trimebutine maleate (TMB) displays a local anesthetic activity higher than that of lidocaine in rabbit corneal reflex. TMB and nor-TMB its main metabolite in human show similar affinity to that of bupivacaine toward sodium channel labeled by [3H]batrachotoxin and block sodium currents in sensory neurons from rat dorsal root ganglia. The aim of this study was to evaluate the effects of TMB and nor-TMB in comparison to lidocaine and bupivacaine in a rat model of acute colonic inflammation induced by trinitrobenzene sulfonic acid (TNBS). A single intracolonic instillation of TNBS (50 mg/kg dissolved in ethanol 30%) led to early plasma extravasation then macroscopic damage (hyperemia and necrosis), increased colonic weight and tissular MPO, a marker of neutrophilic infiltration. Local administration of TMB at dose of 3 to 60 mg/kg, 30 min before, 24 and 48 h after colitis induction, significantly reduced the severity of colitis. Nor-TMB (1, 3, 10, 30 mg/kg) as well as lidocaine (1, 3, 10 mg/kg) dose-dependently reduced colitis while bupivacaine at 10 mg/kg did not affect it significantly. In contrast systemic administration of TMB, nor-TMB and lidocaine at 10 mg/kg had no significant effect. Furthermore, local administration of TMB (30 mg/kg) and lidocaine (10 mg/kg) significantly reduced plasmatic extravasation. In conclusion, intracolonic treatment with TMB and nor-TMB improved acute experimental TNBS-induced colitis in rat and these effects could be explained by their local anesthetic activity.


Subject(s)
Anesthetics, Local/therapeutic use , Colitis/drug therapy , Gastrointestinal Agents/therapeutic use , Trimebutine/analogs & derivatives , Trimebutine/therapeutic use , Administration, Rectal , Animals , Bupivacaine/administration & dosage , Bupivacaine/therapeutic use , Colitis/chemically induced , Colitis/pathology , Colon/drug effects , Colon/pathology , Disease Models, Animal , Dose-Response Relationship, Drug , Gastrointestinal Agents/administration & dosage , Injections, Subcutaneous , Lidocaine/administration & dosage , Lidocaine/therapeutic use , Male , Organ Size/drug effects , Rats , Rats, Sprague-Dawley , Trimebutine/administration & dosage , Trinitrobenzenesulfonic Acid/toxicity
2.
J Pharmacol Exp Ther ; 302(3): 1013-22, 2002 Sep.
Article in English | MEDLINE | ID: mdl-12183658

ABSTRACT

In human, digestive disorders are often associated with visceral pain. In these pathologies, visceral pain threshold is decreased indicating a visceral hypersensitivity. Pregabalin [CI-1008; S-(+)-3-isobutylgaba] presents antihyperalgesic actions in inflammatory somatic pain models. This study was designed to evaluate 1) the effect of injection of TNBS into the colon on visceral pain threshold, and 2) the antihyperalgesic effect of pregabalin on TNBS-induced chronic colonic allodynia. A significant decrease in the colonic pain threshold was observed in trinitrobenzene sulfonic acid (TNBS)-treated animals (17.8 +/- 1.27 versus 43.4 +/- 1.98 mm Hg). Pregabalin (30-200 mg/kg s.c.) and morphine (0.1-1 mg/kg s.c.) showed a dose-related inhibition of TNBS-induced colonic allodynia. Pregabalin did not inhibit the colonic inflammatory effect of TNBS. In normal conditions (control animals), morphine (0.3 mg/kg s.c.) significantly increased the colonic pain threshold, whereas pregabalin (200 mg/kg s.c.) did not modify the colonic pain threshold. Pregabalin suppressed the TNBS-induced colonic allodynia but did not modify the colonic threshold in normal conditions. The ability of pregabalin to block the chronic colonic allodynia indicates that it is effective in abnormal colonic hypersensitivity, suggesting a possible effect in chronic pain in irritable bowel syndrome.


Subject(s)
Colonic Diseases/drug therapy , Pain/drug therapy , Trinitrobenzenesulfonic Acid/antagonists & inhibitors , gamma-Aminobutyric Acid/analogs & derivatives , gamma-Aminobutyric Acid/therapeutic use , Analgesics, Opioid/therapeutic use , Animals , Chronic Disease , Colon/pathology , Colonic Diseases/chemically induced , Colonic Diseases/complications , Hyperemia/chemically induced , Hyperemia/pathology , Male , Morphine/therapeutic use , Organ Size/drug effects , Pain/etiology , Peroxidase/metabolism , Pregabalin , Rats , Rats, Sprague-Dawley , Time Factors , Trinitrobenzenesulfonic Acid/toxicity
SELECTION OF CITATIONS
SEARCH DETAIL
...